Translate Bio (TBIO) to be acquired by Sanofi (SNY) for $3.2 billion

• Sanofi will pay $38 per share in cash, or $3.2 billion
• Translate Bio specializes in messenger RNA technology, the same used by Moderna and BioNTech in their Covid-19 vaccines.
• IPO on  June 28, 2018

 

 

 

 

Already partners, in June 2018 Sanofi and Translate Bio entered into a collaboration and exclusive licence agreement to develop mRNA vaccines, which was further expanded in 2020 to broadly address current and future infectious diseases.

Under the collaboration, there are two ongoing mRNA vaccine clinical trials: the COVID-19 vaccine Phase 1/2 study (with results expected in Q3 2021) and the mRNA seasonal influenza vaccine Phase 1 trial (with results due in Q4 2021).

The acquisition of Massachusetts-based Translate Bio will also help fast track Sanofi’s plans for its recently announced mRNA Centre of Excellence.